GlassScriptPhysician profile
Kavitha Moolamalla
NPI 1629035340
$4,607.09
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $826 · 2021: $1,592 · 2022: $1,161 · 2023: $402 · 2024: $73.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.91 | 2019-2023 | |
| Pfizer INC. | $508.12 | 2019-2022 | |
| Novo Nordisk INC | $363.93 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $274.01 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $212.03 | 2019-2023 | Dificid |
| Esperion Therapeutics, INC. | $180.63 | 2020-2021 | |
| Amgen INC. | $172.39 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $168.18 | 2019-2022 | |
| Eisai INC. | $156.31 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $148.34 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $130.31 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.24 | 2022 | |
| Clarus Therapeutics INC. | $116.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $114.43 | 2022-2024 | Rexulti |
| Allergan, INC. | $109.72 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Moolamalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.